US91307C1027 - Common Stock
Electric aerospace startup Beta Technologies Inc. raised $318 million from investors to fund the production of aircraft that can takeoff and land vertically.
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance.
The company is hoping to launch a drug that rivals United Therapeutics' Tyvaso DPI.
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028!
UTHR stock results show that United Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips United Therapeutics (NASDAQ:UTHR) just reported results for the second quarter ...
The company's earnings came in far below expectations, though sales easily beat.